Tyrosine News and Research

RSS

A rapid and efficient method of identifying neutralizing nanobodies directed against SARS-CoV-2

A recent PLoS ONE study detected neutralizing nanobodies against SARS-CoV-2 from nanobody phage display libraries and via in vitro and ex vivo high-throughput screenings.

2 Sep 2022

SARS-CoV-2 mutational spectra based on reconstructed phylogenetic tree

In a new study, researchers assessed the impact of mutagenesis on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genome and the effects of mutations in the neutral regions and non-neutral regions of the genome.

25 Aug 2022

Scientists begin phase 2 clinical trials of lupus pill

Lupus is an autoimmune disease that attacks organs and can be fatal. There's no cure, so current treatments aim to limit damage and ameliorate symptoms.

22 Aug 2022

Study contributes to better understanding of the changes in kinase activity in renal cell carcinoma

A new research paper was published in Oncotarget on August 4, 2022, entitled, "Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors."

17 Aug 2022

A low-energy, high FODMAP diet in prediabetes and diabetes?

Researchers summarize the available knowledge on FODMAPs and suggest that they can play a role in the prevention and treatment of diabetes.

10 Aug 2022

Study reveals the intertumoral heterogeneity of METex14 skipping positive NSCLCs

A study presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinical-relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping.

8 Aug 2022

Genetic signatures may help predict immunotherapy response in patients with bladder cancer

Investigators from Cedars-Sinai Cancer have identified genetic signatures that could predict whether tumors in patients with bladder and other cancers will respond to immunotherapy.

3 Aug 2022

Researchers discover cell signaling pathway responsible for the development of esophageal cancers

Of the roughly 20,000 people in the U.S. diagnosed with esophageal cancer this year, just 4,000 are likely to still be alive in 2027.

28 Jul 2022

Study: Over half of the online pharmacies selling chemotherapy drugs operate unsafely or illegally

Patients seeking to purchase chemotherapy drugs online face a confusing array of websites, over half of which potentially operate unsafely or illegally, finds a new study in the July 2022 issue of JNCCN-; Journal of the National Comprehensive Cancer Network.

28 Jul 2022

Study shows SARS-CoV-2 impairs interferon production through NSP2-induced repression of mRNA translation

Researchers discovered a SARS-CoV-2 non-structural protein 2 (NSP2)-mediated mechanism by which it suppresses the production of interferon-beta (IFN-β) in host cells.

27 Jul 2022

Scientists identify papain-like protease inhibitor against COVID-19

In a new study, researchers identified a papain-like protease inhibitor for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.

25 Jul 2022

After 3 doses of COVID vaccine, most cancer patients retain detectable humoral immunity

In a recent study posted to the medRxiv* preprint server, researchers assessed the efficacy and durability of immune responses to the third dose of coronavirus disease 2019 (COVID-19) vaccines. They also assessed the efficacy of the fourth vaccine dose among severely immunocompromised patients with hematological malignancies.

7 Jul 2022

UTSA chemistry professor awarded NSF grant to advance research on the body's metabolic processes

Chemistry professor Aimin Liu has been awarded a three-year, $495,000 Accomplishment-Based Renewal (ABR) grant from the National Science Foundation (NSF) to advance his research on the body's metabolic processes using an innovative method that will improve the understanding of amino acids.

1 Jul 2022

BNT162b2 COVID vaccine stimulates significant antibody response in lung cancer patients

In a recent article posted to the medRxiv* preprint server, scientists from Japan assessed the safety and immunogenicity of coronavirus disease 2019 (COVID-19) BNT162b2 vaccine among lung cancer patients under treatment.

28 Jun 2022

Study uncovers cryptic vulnerabilities in RET oncogene that could aid in anti-cancer drug design

RET is a receptor protein with tyrosine kinase activity that can transfer a phosphate group from ATP to other molecules modifying their shape and function in signaling pathways that are essential to organogenesis and tissue maintenance.

24 Jun 2022

New combination of drugs effective against T-cell acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is the most common cancer affecting children. The T-ALL form of leukemia that emerges from early T lineage cells has a poorer prognosis than B-lineage ALL. The prognosis for relapsed T-ALL is very poor and new therapies are sorely needed.

20 Jun 2022

Discovery could lead to more effective treatment for chronic, pathological pain

The world has changed since 1664, when French philosopher and scientist Rene Descartes first claimed the brain was responsible for feeling the sensation of pain.

9 Jun 2022

Ibrutinib plus chemoimmunotherapy prolonged progression-free survival in previously untreated mantle cell lymphoma patients

Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously untreated mantle cell lymphoma (MCL) in patients 65 and over, researchers from The University of Texas MD Anderson Cancer Center reported today at the 2022 American Society of Clinical Oncology Annual Meeting.

3 Jun 2022

New method to combat malaria turns the disease against itself

A new method to combat malaria which sees the disease turn against itself could offer an effective treatment for the hundreds of millions of people infected globally each year, as the efficacy of current antimalarial drugs weakens.